Eli Lilly Healthcare Acquisition | M&A Deal

Eli Lilly has acquired three vaccine makers, a healthcare services other business in the United States, for $4 billion. The targets develop and manufacture vaccines, supporting immunization programs and expanding Lilly’s vaccine pipeline and capabilities across healthcare services other. Eli Lilly acquisitions in vaccine manufacturing strengthen platform acquisition efforts by adding specialized know-how, facilities, and product development capacity. The strategic acquisition is categorized as a platform acquisition and is part of broader healthcare M&A activity by a strategic buyer, with deal terms and expected closing timing to be confirmed.